FDA Brief

Warning letters Drugs

FDA warning letter to

K. Boeun Pharmaceutical Co., Ltd.

High riskIssued Aug 14, 2023Posted Aug 22, 2023Center for Drug Evaluation and Research | CDER

K. Boeun Pharmaceutical's OTC drugs were cited for CGMP violations, including missing identity tests for DEG/EG-risk components and inadequate quality unit.

What happened

FDA reviewed records the company submitted after a March 3, 2023 request and found significant CGMP violations. The company did not show identity testing of each shipment and lot of high-risk components, including glycerin and sorbitol solution, for diethylene glycol (DEG) or ethylene glycol (EG), and its quality unit did not adequately approve or reject components.

What FDA found

  1. The company did not test each incoming shipment and lot of high-risk components, such as glycerin and sorbitol solution, to verify identity and screen for DEG or EG contamination.

    21 CFR 211.84(d)(1)
  2. The quality unit lacked effective authority to approve or reject components and did not adequately oversee the materials system.

    21 CFR 211.22(a)

What FDA wants

FDA tells the company to respond in writing within 30 working days with corrective actions and commitments, including DEG/EG test results within 30 calendar days, a risk assessment, CAPA, material-system review, and quality-unit remediation. If corrective actions cannot be completed within 15 working days, the company must state the reasons and provide a completion schedule.

Who should pay attention

  • brands that use this contract manufacturer for OTC drugs
  • companies sourcing glycerin or sorbitol solution with incomplete identity testing
  • U.S. importers and distributors of OTC drug products

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. Natural Essentials, Inc.

    FDA warns Natural Essentials over OTC drug manufacturing violations, including inadequate failing test result investigations and missing component identity tests.

    High risk
  2. Shenzhen Benliju Biotech Co., Ltd.

    FDA: Shenzhen Benliju Biotech released OTC drugs labeled sterile without sterility testing or process validation.

    High risk
  3. LGM Pharma Solutions, LLC

    FDA warned LGM Pharma Solutions over manufacturing-quality failures in failing-result investigations and process validation for tablets, including a recalled product.

    High risk
  4. Penn Herb Company, Ltd.

    FDA warned Penn Herb Company over CGMP violations and an undeclared tree-nut allergen in three dietary supplements.

    High risk